Literature DB >> 24633869

Imatinib and ruxolitinib association: first experience in two patients.

Alessandra Iurlo1, Umberto Gianelli2, Davide Rapezzi3, Daniele Cattaneo4, Elisa Fermo4, Francesca Binda4, Elisa Santambrogio4, Cristina Bucelli4, Agostino Cortelezzi4.   

Abstract

Entities:  

Keywords:  chronic myeloid leukemia; imatinib; myelofibrosis; post-polycythemia vera; ruxolitinib

Mesh：

Substances：

Year:  2014        PMID： 24633869      PMCID： PMC4040897          DOI： 10.3324/haematol.2013.102525

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

Authors:  B J Druker; N B Lydon
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Long-term outcome of treatment with ruxolitinib in myelofibrosis.

Authors:  Ayalew Tefferi; Mark R Litzow; Animesh Pardanani
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

3.  JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

Authors:  N Cambier; A Renneville; T Cazaentre; V Soenen; C Cossement; S Giraudier; N Grardel; J-L Laï; C Rose; C Preudhomme
Journal:  Leukemia       Date:  2008-02-21       Impact factor: 11.528

4.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

5.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

Review 6.  Advances in myelofibrosis: a clinical case approach.

Authors:  John O Mascarenhas; Attilio Orazi; Kapil N Bhalla; Richard E Champlin; Claire Harrison; Ronald Hoffman
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

7.  European consensus on grading bone marrow fibrosis and assessment of cellularity.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Fabio Facchetti; Vito Franco; Jon van der Walt; Attilio Orazi
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

8.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

9.  Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

Authors:  Claire Harrison; Alessandro M Vannucchi
Journal:  Ther Adv Hematol       Date:  2012-12

10.  Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.

Authors:  Laurent Jallades; Sandrine Hayette; Isabelle Tigaud; Anna Johnston; Bertrand Coiffier; Jean-Pierre Magaud; Martine Ffrench
Journal:  Leuk Res       Date:  2008-04-29       Impact factor: 3.156
View more
  5 in total

1.  Busy signal: platelet-derived growth factor activation in myelofibrosis.

Authors:  Anna E Marneth; Ann Mullally
Journal:  Haematologica       Date:  2020-08       Impact factor: 9.941

2.  Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis.

Authors:  Abdulraheem Yacoub; Lindsey Prochaska
Journal:  Biomark Res       Date:  2016-02-05

3.  Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Authors:  A Zhou; E M Knoche; E K Engle; D A C Fisher; S T Oh
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

Review 4.  Treatment of Myelofibrosis: Old and New Strategies.

Authors:  Alessandra Iurlo; Daniele Cattaneo
Journal:  Clin Med Insights Blood Disord       Date:  2017-03-08

Review 5.  Cytokines frequently implicated in myeloproliferative neoplasms.

Authors:  Yingying Wang; Xuelan Zuo
Journal:  Cytokine X       Date:  2019-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.